For-Robin

Executive Summary

For-Robin is a private, preclinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company specializes in developing antibody-based biologics, with its current focus on enabling clinical imaging trials through IND-enabling antibody production and safety studies. For-Robin is collaborating with the NCI's NExT program to advance its platform. The company's mission is rooted in a personal journey to combat cancer metastasis. As a preclinical entity with no disclosed funding or pipeline details, For-Robin represents an early-stage opportunity with high risk but potential upside if its imaging antibody candidates succeed in enabling clinical trials. The partnership with a prominent national program provides some validation, but the lack of public data on financials or specific programs limits visibility.

Upcoming Catalysts (preview)

• Q3 2026Initiation of IND-enabling studies for lead imaging antibody60% success
• Q4 2026Series A funding round or grant announcement50% success
• Q1 2027Publication of preclinical proof-of-concept data in a peer-reviewed journal70% success